<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377897</url>
  </required_header>
  <id_info>
    <org_study_id>OPTIPEC</org_study_id>
    <nct_id>NCT00377897</nct_id>
  </id_info>
  <brief_title>Cell Therapy With Bone Marrow Mononuclear Cells in Critical Leg Ischemia (CLI)</brief_title>
  <official_title>Optimisation d'un Produit de thérapie Cellulaire Autologue Par Cellules mononucléées médullaires Dans l'ischémie Critique Des Membres inférieurs liée à l'athérosclérose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Paris 5 - Rene Descartes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Paris 5 - Rene Descartes</source>
  <brief_summary>
    <textblock>
      This study will treat by cell therapy 20 patients with critical leg ischemia (CLI) not
      eligible for revascularization or angioplasty. It will use exactly the same protocol as
      published by Tateishi-Yuyama et al. (Lancet 2002), using bone-marrow mononuclear cells
      (BMMNC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be included with CLI according to the TASC criteria. Under general anesthesia,
      500 ml of bone marrow is harvested in both iliac crests. After isolation and concentration of
      the BMMNC in 30 ml, 40 injections of around 0.75 ml will be done in the gastrocnemius of the
      ischemic leg, within 3 hours after preparation of the cell therapy product.

      Patients will then be followed-up every week during one month and then every month during one
      year.

      This study was approved by the ethical committee of Paris-Broussais HEGP (France) and our
      french regulatory agency (AFSSAPS).

      It began including patients in January 2005 and will last until December 2007.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2005</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ankle brachial index</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Healing</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amputation rate</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TcPO2</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Critical Leg Ischemia</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cell therapy</intervention_name>
    <description>Injection of Bone-Marrow mononuclear cells in the muscles of the calf.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18

          -  Signature of informed consent

          -  Critical leg ischemia with ankle pressure &lt; 70 mmHg

          -  Ischemic ulcer or gangrene

          -  No possibility of surgical revascularization

          -  No possibility of angioplasty

        Exclusion Criteria:

          -  Cancer

          -  Suspicion of a cancer on X-Ray, mammography or elevated PSA

          -  Age &lt; 18

          -  Life expectancy &lt; 6 months

          -  Active retinopathy

          -  Angioplasty or surgical revascularization within 3 months

          -  Stoke within 3 months

          -  HIV + or HCV/HBC+
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Emmerich</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph Emmerich, MD, PhD</last_name>
    <phone>33 1 56 09 30 51</phone>
    <email>joseph.emmerich@egp.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saliha Djane, MD</last_name>
    <phone>33 1 44 84 17 45</phone>
    <email>saliha.djane@sls.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emmerich</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2006</study_first_submitted>
  <study_first_submitted_qc>September 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2006</study_first_posted>
  <last_update_submitted>February 13, 2009</last_update_submitted>
  <last_update_submitted_qc>February 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>DRC</name_title>
    <organization>APHP</organization>
  </responsible_party>
  <keyword>critical leg ischemia</keyword>
  <keyword>PAD</keyword>
  <keyword>cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

